Patient presents with symptoms suggestive of a myeloproliferative neoplasm (MPN).  These include fatigue, splenomegaly, pruritus, early satiety, and night sweats.  Complete blood count reveals elevated hemoglobin and hematocrit, leukocytosis, and thrombocytosis.  Bone marrow biopsy demonstrates hypercellularity with a predominance of myeloid lineage cells.  Molecular testing reveals the presence of the JAK2 V617F mutation, confirming the diagnosis of a Philadelphia chromosome-negative MPN.  Differential diagnoses considered include polycythemia vera, essential thrombocythemia, and primary myelofibrosis.  Given the patient's clinical presentation and laboratory findings, polycythemia vera is the most likely diagnosis.  Treatment plan includes phlebotomy to maintain hematocrit below 45, low-dose aspirin for thrombotic prophylaxis, and consideration of cytoreductive therapy with hydroxyurea if indicated by high-risk features such as age over 60 or history of thrombosis.  Patient education provided on disease management, including risk factors for thrombosis, symptom management, and the importance of regular follow-up.  ICD-10 code D45.1 (Polycythemia vera) assigned.  Follow-up scheduled in two weeks to monitor hematocrit and assess response to therapy.


Patient presents with complaints of fatigue, abdominal fullness, and early satiety. Physical examination reveals palpable splenomegaly.  Complete blood count demonstrates thrombocytosis, with platelet count exceeding 1 millionmcL.  Bone marrow biopsy shows megakaryocytic hyperplasia with large, hyperlobulated megakaryocytes.  JAK2, CALR, and MPL mutation analysis is pending.  Differential diagnosis includes essential thrombocythemia, reactive thrombocytosis, and other myeloproliferative neoplasms.  Given the patient's clinical picture and laboratory findings, essential thrombocythemia is suspected.  Plan includes monitoring platelet counts, assessment of thrombotic risk factors, and initiation of aspirin therapy for low-risk patients.  Cytoreductive therapy with hydroxyurea or interferon will be considered if the patient is high risk, based on age, prior thrombotic events, or extreme thrombocytosis.  Patient education provided regarding signs and symptoms of thrombosis and the importance of adhering to the treatment plan.  ICD-10 code D47.3 (Essential thrombocythemia) will be assigned pending molecular testing confirmation.  Follow-up scheduled in one month for repeat blood counts and review of molecular testing results. 

Patient reports progressive fatigue, weight loss, and increasing abdominal discomfort.  Examination reveals splenomegaly and hepatomegaly.  Peripheral blood smear reveals leukoerythroblastosis and teardrop poikilocytosis.  Bone marrow biopsy reveals increased reticulin fibrosis, consistent with primary myelofibrosis.  Molecular testing for JAK2, CALR, and MPL mutations is ordered.  Differential diagnosis includes other myeloproliferative neoplasms, myelodysplastic syndromes, and secondary myelofibrosis.  Given the clinical and laboratory findings, primary myelofibrosis is the presumptive diagnosis.  Supportive care measures initiated, including transfusions for anemia and symptomatic splenomegaly.  Ruxolitinib therapy is being considered to address splenomegaly and constitutional symptoms. Allogeneic stem cell transplantation will be discussed as a potential curative option.  ICD-10 code D47.1 (Chronic idiopathic myelofibrosis) assigned.  Referral to hematology specialist made for further management and consideration of clinical trials.  Follow-up appointment scheduled in two weeks to monitor symptoms and blood counts.